ROCO
4121
Market cap35mUSD
Jul 09, Last price
13.30TWD
1D
-1.12%
1Q
-14.47%
Jan 2017
12.14%
IPO
-33.00%
Name
Rossmax International Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rossmax International Ltd. is dedicated to creating and delivering a wide array of healthcare products and solutions. Their diverse product lineup includes advanced diagnostic and monitoring devices such as body composition scales, which provide readings for body fat, BMI, lean mass, muscle mass, water ratio, and overall body weight. They also offer various blood pressure monitors, including traditional sphygmomanometers, stethoscopes for internal sound auscultation, portable pulse oximeters for tracking blood oxygen saturation, non-contact infrared thermometers, and blood glucose monitoring systems for diabetes management. The company further extends its offerings to therapeutic and assistive medical equipment. This includes nebulizers for mist-based medication delivery, suction units for removing bodily fluids, aero spacers to enhance aerosolized drug administration, peak flow meters for respiratory function assessment, therapeutic heating pads, and anti-decubitus mattresses. Complementing its hardware, Rossmax provides the Healthstyle app, a unified digital platform enabling users to conveniently track key health metrics like blood pressure, blood glucose, SpO2, weight, and temperature. Rossmax's solutions cater to a broad spectrum of medical fields, including cardiovascular health, diabetes, respiratory conditions, fever management, and wound care. They also offer a specialized range of thermometers, scales, and nebulizers specifically designed for pediatric use. Founded in 1988 and headquartered in Taipei, Taiwan, Rossmax International Ltd. operates with a strong global footprint. The company exports its products and maintains active operations in numerous international markets, spanning Taiwan, Italy, Brazil, Mainland China, Germany, Ukraine, Poland, Iraq, India, the United Kingdom, Japan, and Turkey.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||